For the boys, prostate cancer screening is another case in point. Screening is easy (just a blood test - a PSA) but like all screening programs it is plagued by overdiagnosis, and the harms from treatment for this condition are also quite significant (high rates of incontinence and erectile dysfunction).
The difference between this and breast cancer screening is that there is less general acceptance, and more criticism from official bodies and major academic and popular journals, and also from the guy who invented the PSA test in the first place (here).
The large scale randomised trials (the best evidence) on this topic give conflicting results regarding the effectiveness, and again, they concentrate on disease-specific mortality (which always makes screening look better), rather than overall mortality.
For the best explanation of the relative risks and benefits of PSA screening, read this article from some excellent public health academics from Australia, who put the risks and harms into numbers, to make it more digestible. They conclude:
“you have to screen 1408 men and treat an additional 48 men to prevent one prostate cancer death over 9 years. In other words, only 1 of those 48 men is going to benefit over the next 9 years; the other 47 … have undergone treatment for no benefit within this period.”